Tofacitinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4124 publications

Advances in clinical management of acute severe ulcerative colitis

Advances in clinical management of acute severe ulcerative colitis

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Published: April 13, 2026

Inflammatory Linear Verrucous Epidermal Nevus Refractory to IL-17A Blockade but Responsive to Tofacitinib.

Inflammatory Linear Verrucous Epidermal Nevus Refractory to IL-17A Blockade but Responsive to Tofacitinib.

Journal: American journal of therapeutics

Published: April 09, 2026

A Rationally Designed Novel Bifunctional Human TNF-α- and Janus Kinase-Targeted soloMER Drug Conjugate (SDC) with a Neutrophil Elastase Cleavable Linker Delivering Inflammation Site-Specific Release of Payload.

A Rationally Designed Novel Bifunctional Human TNF-α- and Janus Kinase-Targeted soloMER Drug Conjugate (SDC) with a Neutrophil Elastase Cleavable Linker Delivering Inflammation Site-Specific Release of Payload.

Journal: Journal of medicinal chemistry

Published: April 07, 2026

Rapid Clearance of Lichen Planus With Topical Tapinarof.

Rapid Clearance of Lichen Planus With Topical Tapinarof.

Journal: Journal of drugs in dermatology : JDD

Published: April 03, 2026

Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study.

Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study.

Journal: The Journal of dermatological treatment

Published: April 01, 2026

Identification of an Orally Bioavailable Quinoline-Based Small-Molecule Tumor Necrosis Factor α (TNF-α) Inhibitor Featuring a Spirocyclic Scaffold.

Identification of an Orally Bioavailable Quinoline-Based Small-Molecule Tumor Necrosis Factor α (TNF-α) Inhibitor Featuring a Spirocyclic Scaffold.

Journal: Journal of medicinal chemistry

Published: March 31, 2026

Acquired Perforating Dermatoses Associated With Biologics and Janus Kinase Inhibitor Therapy: A Systematic Review.

Acquired Perforating Dermatoses Associated With Biologics and Janus Kinase Inhibitor Therapy: A Systematic Review.

Journal: Journal of cutaneous medicine and surgery

Published: March 27, 2026

Advances in the use of Janus kinase inhibitors.

Advances in the use of Janus kinase inhibitors.

Journal: Current opinion in rheumatology

Published: March 17, 2026

Cardiovascular risk and JAK inhibitor for the treatment of spondyloarthritis: A systematic review protocol.

Cardiovascular risk and JAK inhibitor for the treatment of spondyloarthritis: A systematic review protocol.

Journal: La Tunisie medicale

Published: March 15, 2026

Reactive granulomatous dermatitis arising in the setting of interleukin-17 inhibition successfully treated with tofacitinib.

Reactive granulomatous dermatitis arising in the setting of interleukin-17 inhibition successfully treated with tofacitinib.

Journal: JAAD case reports

Published: March 05, 2026

Atypical Prurigo Pigmentosa Following Ketogenic Diet: Successful Treatment with Doxycycline and Tofacitinib.

Atypical Prurigo Pigmentosa Following Ketogenic Diet: Successful Treatment with Doxycycline and Tofacitinib.

Journal: Acta dermato-venereologica

Published: March 04, 2026

CYTOMEGALOVIRUS RETINITIS IN NON-HIV IMMUNOCOMPROMISED INDIVIDUALS ON TOFACITINIB FOR RHEUMATOID ARTHRITIS.

CYTOMEGALOVIRUS RETINITIS IN NON-HIV IMMUNOCOMPROMISED INDIVIDUALS ON TOFACITINIB FOR RHEUMATOID ARTHRITIS.

Journal: Retinal cases & brief reports

Published: March 04, 2026

Showing 1-12 of 4,124

Last Updated: 04/28/2026